The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.
Daniel Virgil Thomas Catenacci
Honoraria - Genentech/Roche
Nathan Bahary
No relevant relationships to disclose
Sreenivasa R. Nattam
No relevant relationships to disclose
Robert de Wilton Marsh
No relevant relationships to disclose
James Alfred Wallace
No relevant relationships to disclose
Lakshmi Rajdev
No relevant relationships to disclose
Deirdre Jill Cohen
Honoraria - Genentech
Bethany G. Sleckman
No relevant relationships to disclose
Heinz-Josef Lenz
No relevant relationships to disclose
Patrick J. Stiff
No relevant relationships to disclose
Sachdev P. Thomas
No relevant relationships to disclose
Peng Xu
No relevant relationships to disclose
Les Henderson
No relevant relationships to disclose
Margit Naomi Horiba
No relevant relationships to disclose
Michael Vannier
No relevant relationships to disclose
Theodore Karrison
No relevant relationships to disclose
Walter Michael Stadler
No relevant relationships to disclose
Hedy Lee Kindler
Consultant or Advisory Role - Genentech
Research Funding - Genentech